Advertisement

Aspects of cAMP Signaling in Epileptogenesis and Seizures and Its Potential as Drug Target

  • Christoffer Mertz
  • Sara Krarup
  • Cecilie D. Jensen
  • Sandy E. H. Lindholm
  • Christina Kjær
  • Lars H. Pinborg
  • Lasse K. BakEmail author
Review

Abstract

Epilepsy is one of the most common chronic neurological conditions. Today, close to 30 different medications to prevent epileptic seizures are in use; yet, far from all patients become seizure free upon medical treatment. Thus, there is a need for new pharmacological approaches including novel drug targets for the management of epilepsy. Despite the fact that a role for cAMP signaling in epileptogenesis and seizures was first suggested some four decades ago, none of the current medications target the cAMP signaling system. The reasons for this are probably many including limited knowledge of the underlying biology and pathology as well as difficulties in designing selective drugs for the different components of the cAMP signaling system. This review explores selected aspects of cAMP signaling in the context of epileptogenesis and seizures including cAMP response element binding (CREB)-mediated transcriptional regulation. We discuss the therapeutic potential of targeting cAMP signaling in epilepsy and point to an increased knowledge of the A-kinase anchoring protein-based signaling hubs as being of seminal importance for future drug discovery within the field. Further, in terms of targeting CREB, we argue that targeting upstream cAMP signals might be more fruitful than targeting CREB itself. Finally, we point to astrocytes as cellular targets in epilepsy since cAMP signals may regulate astrocytic K+ clearance affecting neuronal excitability.

Keywords

Epilepsy Seizure Epileptogenesis cAMP 

Notes

Funding

Funding were provided by Hørslev-Fonden (Grant No. 203866-MAS/mbs1), the Lundbeck Foundation via the Drug Research Academy at University of Copenhagen, Oda og Hans Svenningsens Fond (DK) and P. A. Messerschmidt og Hustrus Fond (DK).

References

  1. 1.
    Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR (2010) Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia 51:883–890Google Scholar
  2. 2.
    Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, Engel J Jr, Forsgren L, French JA, Glynn M, Hesdorffer DC, Lee BI, Mathern GW, Moshé SL, Perucca E, Scheffer IE, Tomson T, Watanabe M, Wiebe S (2014) ILAE Official Report: a practical clinical definition of epilepsy. Epilepsia 55:475–482Google Scholar
  3. 3.
    Fisher RS, van Emde Boas W, Blume W, Elger C, Genton P, Lee P, Engel J Jr (2005) Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 46:470–472Google Scholar
  4. 4.
    Beghi E, Berg A, Carpio A, Forsgren L, Hesdorffer DC, Hauser WA, Malmgren K, Shinnar S, Temkin N, Thurman D, Tomson T (2005) Comment on epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia 46:1698–1699 (author reply 1701–1692)Google Scholar
  5. 5.
    Thijs RD, Surges R, O'Brien TJ, Sander JW (2019) Epilepsy in adults. Lancet 393:689–701Google Scholar
  6. 6.
    Varvel NH, Jiang J, Dingledine R (2015) Candidate drug targets for prevention or modification of epilepsy. Annu Rev Pharmacol Toxicol 55:229–247Google Scholar
  7. 7.
    Kwan P, Brodie MJ (2000) early identification of refractory epilepsy. N Engl J Med 342:314–319Google Scholar
  8. 8.
    Chen Z, Brodie MJ, Liew D, Kwan P (2018) Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol 75:279–286Google Scholar
  9. 9.
    Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Moshé SL, Perucca E, Wiebe S, French J (2010) Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE Commission on Therapeutic Strategies. Epilepsia 51:1069–1077Google Scholar
  10. 10.
    Kwan P, Schachter SC, Brodie MJ (2011) Drug-Resistant epilepsy. N Engl J Med 365:919–926Google Scholar
  11. 11.
    Rogawski MA, Löscher W (2004) The neurobiology of antiepileptic drugs. Nat Rev Neurosci 5:553Google Scholar
  12. 12.
    Perucca P, Mula M (2013) Antiepileptic drug effects on mood and behavior: molecular targets. Epilepsy Behav 26:440–449Google Scholar
  13. 13.
    Löscher W, Schmidt D (2011) Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 52:657–678Google Scholar
  14. 14.
    Ryvlin P, Cucherat M, Rheims S (2011) Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials. Lancet Neurol 10:961–968Google Scholar
  15. 15.
    Faught E, Duh MS, Weiner JR, Guérin A, Cunnington MC (2008) Nonadherence to antiepileptic drugs and increased mortality. Neurology 71:1572Google Scholar
  16. 16.
    Stephen LJ, Forsyth M, Kelly K, Brodie MJ (2012) Antiepileptic drug combinations–have newer agents altered clinical outcomes? Epilepsy Res 98:194–198Google Scholar
  17. 17.
    Wasterlain CG, Csiszar E (1980) Cyclic nucleotide metabolism in mouse brain during seizures induced by bicuculline or dibutyryl cyclic guanosine monophosphate. Exp Neurol 70:260–268Google Scholar
  18. 18.
    Ferrendelli JA, Blank AC, Gross RA (1980) Relationships between seizure activity and cyclic nucleotide levels in brain. Brain Res 200:93–103Google Scholar
  19. 19.
    Boulton CL, McCrohan CR, O'Shaughnessy CT (1993) Cyclic AMP analogues increase excitability and enhance epileptiform activity in rat neocortex in vitro. Eur J Pharmacol 236:131–136Google Scholar
  20. 20.
    Zhang Y, Gao B, Zheng F, Lu S, Li Y, Xiong Y, Yang Q, Yang Y, Fu P, Xiao F, Wang X (2017) The phosphodiesterase 10A inhibitor PF-2545920 enhances hippocampal excitability and seizure activity involving the upregulation of GluA1 and NR2A in post-synaptic densities. Front Mol Neurosci 10:100Google Scholar
  21. 21.
    Guelfi S, Botia JA, Thom M, Ramasamy A, Perona M, Stanyer L, Martinian L, Trabzuni D, Smith C, Walker R, Ryten M, Reimers M, Weale ME, Hardy J, Matarin M (2019) Transcriptomic and genetic analyses reveal potential causal drivers for intractable partial epilepsy. Brain 142:1616–1630Google Scholar
  22. 22.
    Kjær C, Barzaghi G, Bak LK, Goetze JP, Yde CW, Woldbye DP, Pinborg LH, Jensen LJ (2019) Transcriptome analysis in patients with temporal lobe epilepsy and hippocampal sclerosis. Brain.  https://doi.org/10.1093/brain/awz265 Google Scholar
  23. 23.
    Halls ML, Cooper DMF (2011) Regulation by Ca2+-signaling pathways of adenylyl cyclases. Csh Perspect Biol 3:273–294Google Scholar
  24. 24.
    Francis SH, Blount MA, Corbin JD (2011) Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev 91:651–690Google Scholar
  25. 25.
    Kamenetsky M, Middelhaufe S, Bank EM, Levin LR, Buck J, Steegborn C (2006) Molecular details of cAMP generation in mammalian cells: a tale of two systems. J Mol Biol 362:623–639Google Scholar
  26. 26.
    Dessauer CW (2009) Adenylyl cyclase–A-kinase anchoring protein complexes: the next dimension in cAMP signaling. Mol Pharmacol 76:935–941Google Scholar
  27. 27.
    Bauer PR, Kalitzin S, Zijlmans M, Sander JW, Visser GH (2014) Cortical excitability as a potential clinical marker of epilepsy: a review of the clinical application of transcranial magnetic stimulation. Int J Neural Syst 24:1430001Google Scholar
  28. 28.
    Badawy RA, Harvey AS, Macdonell RA (2009) Cortical hyperexcitability and epileptogenesis: understanding the mechanisms of epilepsy—part 1. J Clin Neurosci 16:355–365Google Scholar
  29. 29.
    Greengard P, Jen J, Nairn A, Stevens C (1991) Enhancement of the glutamate response by cAMP-dependent protein kinase in hippocampal neurons. Science 253:1135–1138Google Scholar
  30. 30.
    Higashima M, Ohno K, Koshino Y (2002) Cyclic AMP-mediated modulation of epileptiform afterdischarge generation in rat hippocampal slices. Brain Res 949:157–161Google Scholar
  31. 31.
    Lopes MW, Lopes SC, Costa AP, Goncalves FM, Rieger DK, Peres TV, Eyng H, Prediger RD, Diaz AP, Nunes JC, Walz R, Leal RB (2015) Region-specific alterations of AMPA receptor phosphorylation and signaling pathways in the pilocarpine model of epilepsy. Neurochem Int 87:22–33Google Scholar
  32. 32.
    Rakhade SN, Zhou C, Aujla PK, Fishman R, Sucher NJ, Jensen FE (2008) Early alterations of AMPA receptors mediate synaptic potentiation induced by neonatal seizures. J Neurosci 28:7979–7990Google Scholar
  33. 33.
    Roche KW, O'Brien RJ, Mammen AL, Bernhardt J, Huganir RL (1996) Characterization of multiple phosphorylation sites on the AMPA receptor GluR1 subunit. Neuron 16:1179–1188Google Scholar
  34. 34.
    Zhang M, Patriarchi T, Stein IS, Qian H, Matt L, Nguyen M, Xiang YK, Hell JW (2013) Adenylyl cyclase anchoring by a kinase anchor protein AKAP5 (AKAP79/150) is important for postsynaptic beta-adrenergic signaling. J Biol Chem 288:17918–17931Google Scholar
  35. 35.
    Efendiev R, Samelson BK, Nguyen BT, Phatarpekar PV, Baameur F, Scott JD, Dessauer CW (2010) AKAP79 interacts with multiple adenylyl cyclase (AC) isoforms and scaffolds AC5 and -6 to alpha-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) receptors. J Biol Chem 285:14450–14458Google Scholar
  36. 36.
    Derkach V, Barria A, Soderling TR (1999) Ca2+/calmodulin-kinase II enhances channel conductance of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate type glutamate receptors. Proc Natl Acad Sci USA 96:3269–3274Google Scholar
  37. 37.
    He K, Song L, Cummings LW, Goldman J, Huganir RL, Lee H-K (2009) Stabilization of Ca2+-permeable AMPA receptors at perisynaptic sites by GluR1-S845 phosphorylation. Proc Natl Acad Sci USA 106:20033–20038Google Scholar
  38. 38.
    Zhu X, Han X, Blendy JA, Porter BE (2012) Decreased CREB levels suppress epilepsy. Neurobiol Dis 45:253–263Google Scholar
  39. 39.
    Shaywitz AJ, Greenberg ME (1999) CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. Annu Rev Biochem 68:821–861Google Scholar
  40. 40.
    Hu B, Liu C, Bramlett H, Sick TJ, Alonso OF, Chen S, Dietrich WD (2004) Changes in TrkB–ERK1/2–CREB/Elk-1 pathways in hippocampal mossy fiber organization after traumatic brain injury. J Cereb Blood Flow Metab 24:934–943Google Scholar
  41. 41.
    Marson AG, Carr D, Miyajima F, Sills GJ, Pirmohamed M, Mirza N, Appleton R, Burn S, Crooks D, du Plessis D, Duncan R, Farah JO, Josan V, Shukralla A, Mohanraj R (2015) Identifying the biological pathways underlying human focal epilepsy: from complexity to coherence to centrality. Hum Mol Genet 24:4306–4316Google Scholar
  42. 42.
    Rakhade SN, Yao B, Ahmed S, Asano E, Beaumont TL, Shah AK, Draghici S, Krauss R, Chugani HT, Sood S, Loeb JA (2005) A common pattern of persistent gene activation in human neocortical epileptic foci. Ann Neurol 58:736–747Google Scholar
  43. 43.
    Floriano-Sanchez E, Brindis F, Ortega-Cuellar D, Ignacio-Mejia I, Moreno-Arriola E, Romero-Morelos P, Ceballos-Vasquez E, Cordova-Espinoza MG, Arregoitia-Sarabia CK, Sandoval-Pacheco R, Carmona-Aparicio L, Cardenas-Rodriguez N (2018) Differential gene expression profile induced by valproic acid (VPA) in pediatric epileptic patients. Genes 9:328Google Scholar
  44. 44.
    Lopez de Armentia M, Jancic D, Olivares R, Alarcon JM, Kandel ER, Barco A (2007) cAMP response element-binding protein-mediated gene expression increases the intrinsic excitability of CA1 pyramidal neurons. J Neurosci 27:13909Google Scholar
  45. 45.
    Porter BE, Lund IV, Varodayan FP, Wallace RW, Blendy JA (2008) The role of transcription factors cyclic-AMP responsive element modulator (CREM) and inducible cyclic-AMP early repressor (ICER) in epileptogenesis. Neuroscience 152:829–836Google Scholar
  46. 46.
    Kojima N, Borlikova G, Sakamoto T, Yamada K, Ikeda T, Itohara S, Niki H, Endo S (2008) Inducible cAMP early repressor acts as a negative regulator for kindling epileptogenesis and long-term fear memory. J Neurosci 28:6459Google Scholar
  47. 47.
    Cooper DMF, Mons N, Karpen JW (1995) Adenylyl cyclases and the interaction between calcium and cAMP signalling. Nature 374:421–424Google Scholar
  48. 48.
    Chen X, Dong G, Zheng C, Wang H, Yun W, Zhou X (2016) A reduced susceptibility to chemoconvulsant stimulation in adenylyl cyclase 8 knockout mice. Epilepsy Res 119:24–29Google Scholar
  49. 49.
    Willoughby D, Cooper DM (2007) Organization and Ca2+ regulation of adenylyl cyclases in cAMP microdomains. Physiol Rev 87:965–1010Google Scholar
  50. 50.
    Halls ML, Cooper DM (2011) Regulation by Ca2+-signaling pathways of adenylyl cyclases. Cold Spring Harbor Perspect Biol 3:a004143Google Scholar
  51. 51.
    Fagan KA, Graf RA, Tolman S, Schaack J, Cooper DM (2000) Regulation of a Ca2+-sensitive adenylyl cyclase in an excitable cell. Role of voltage-gated versus capacitative Ca2+ entry. J Biol Chem 275:40187–40194Google Scholar
  52. 52.
    Wong ST, Athos J, Figueroa XA, Pineda VV, Schaefer ML, Chavkin CC, Muglia LJ, Storm DR (1999) Calcium-stimulated adenylyl cyclase activity is critical for hippocampus-dependent long-term memory and late phase LTP. Neuron 23:787–798Google Scholar
  53. 53.
    DiRocco DP, Scheiner ZS, Sindreu CB, Chan GC, Storm DR (2009) A role for calmodulin-stimulated adenylyl cyclases in cocaine sensitization. J Neurosci 29:2393–2403Google Scholar
  54. 54.
    Wang H, Gong B, Vadakkan KI, Toyoda H, Kaang BK, Zhuo M (2007) Genetic evidence for adenylyl cyclase 1 as a target for preventing neuronal excitotoxicity mediated by N-methyl-D-aspartate receptors. J Biol Chem 282:1507–1517Google Scholar
  55. 55.
    Reuschlein AK, Jakobsen E, Mertz C, Bak LK (2019) Aspects of astrocytic cAMP signaling with an emphasis on the putative power of compartmentalized signals in health and disease. Glia 67(9):1625–1636.  https://doi.org/10.1002/glia.23622 Google Scholar
  56. 56.
    Nedergaard M, Rodriguez JJ, Verkhratsky A (2010) Glial calcium and diseases of the nervous system. Cell Calcium 47:140–149Google Scholar
  57. 57.
    Bak LK, Walls AB, Schousboe A, Waagepetersen HS (2018) Astrocytic glycogen metabolism in the healthy and diseased brain. J Biol Chem 293:7108–7116Google Scholar
  58. 58.
    Rivera-Pagan AF, Mendez-Gonzalez MP, Rivera-Aponte DE, Malpica-Nieves CJ, Melnik-Martinez KV, Zayas-Santiago A, Maldonado-Martinez G, Shuba YM, Skatchkov SN, Eaton MJ (2018) A-kinase-anchoring protein (AKAP150) is expressed in astrocytes and upregulated in response to ischemia. Neuroscience 384:54–63Google Scholar
  59. 59.
    Sanchez Fernandez I, Goodkin HP, Scott RC (2018) Pathophysiology of convulsive status epilepticus. Seizure 68:16–21Google Scholar
  60. 60.
    Farrell JS, Colangeli R, Wolff MD, Wall AK, Phillips TJ, George A, Federico P, Teskey GC (2017) Postictal hypoperfusion/hypoxia provides the foundation for a unified theory of seizure-induced brain abnormalities and behavioral dysfunction. Epilepsia 58:1493–1501Google Scholar
  61. 61.
    Farrell JS, Gaxiola-Valdez I, Wolff MD, David LS, Dika HI, Geeraert BL, Rachel Wang X, Singh S, Spanswick SC, Dunn JF, Antle MC, Federico P, Teskey GC (2016) Postictal behavioural impairments are due to a severe prolonged hypoperfusion/hypoxia event that is COX-2 dependent. Elife 5:e19352Google Scholar
  62. 62.
    Palmer GC (1979) Interactions of antiepileptic drugs on adenylate cyclase and phosphodiesterases in rat and mouse cerebrum. Exp Neurol 63:322–335Google Scholar
  63. 63.
    Ambrósio AF, Soares-da-Silva P, Carvalho CM, Carvalho AP (2002) Mechanisms of action of carbamazepine and its derivatives, oxcarbazepine, BIA 2–093, and BIA 2–024. Neurochem Res 27:121–130Google Scholar
  64. 64.
    Soderpalm B (2002) Anticonvulsants: aspects of their mechanisms of action. Eur J Pain 6(Suppl A):3–9Google Scholar
  65. 65.
    Spina E, Perugi G (2004) Antiepileptic drugs: indications other than epilepsy. Epileptic Disord 6:57–75Google Scholar
  66. 66.
    Chen G, Pan B, Hawver DB, Wright CB, Potter WZ, Manji HK (1996) Attenuation of cyclic AMP production by carbamazepine. J Neurochem 67:2079–2086Google Scholar
  67. 67.
    Chang P, Chandler KE, Williams RS, Walker MC (2010) Inhibition of long-term potentiation by valproic acid through modulation of cyclic AMP. Epilepsia 51:1533–1542Google Scholar
  68. 68.
    Mann L, Heldman E, Bersudsky Y, Vatner SF, Ishikawa Y, Almog O, Belmaker RH, Agam G (2009) Inhibition of specific adenylyl cyclase isoforms by lithium and carbamazepine, but not valproate, may be related to their antidepressant effect. Bipolar Disord 11:885–896Google Scholar
  69. 69.
    Montezinho LP, Mørk A, Duarte CB, Penschuck S, Geraldes CF, Castro MMC (2007) Effects of mood stabilizers on the inhibition of adenylate cyclase via dopamine D2-like receptors. Bipolar Disord 9:290–297Google Scholar
  70. 70.
    Gallagher HC, Bacon CL, Odumeru OA, Gallagher KF, Fitzpatrick T, Regan CM (2004) Valproate activates phosphodiesterase-mediated cAMP degradation: relevance to C6 glioma G1 phase progression. Neurotoxicol Teratol 26:73–81Google Scholar
  71. 71.
    Fujiwara Y, Sato M, Otsuki S (1986) Interaction of carbamazepine and other drugs with adenosine (A1 and A2) receptors. Psychopharmacology 90:332–335Google Scholar
  72. 72.
    Du J, Gray NA, Falke CA, Chen W, Yuan P, Szabo ST, Einat H, Manji HK (2004) Modulation of synaptic plasticity by antimanic agents: the role of AMPA glutamate receptor subunit 1 synaptic expression. J Neurosci 24:6578–6589Google Scholar
  73. 73.
    Chen G, Manji HK, Wright CB, Hawver DB, Potter WZ (1996) Effects of valproic acid on beta-adrenergic receptors, G-proteins, and adenylyl cyclase in rat C6 glioma cells. Neuropsychopharmacology 15:271–280Google Scholar
  74. 74.
    Zhu X, Dubey D, Bermudez C, Porter BE (2015) Suppressing cAMP response element-binding protein transcription shortens the duration of status epilepticus and decreases the number of spontaneous seizures in the pilocarpine model of epilepsy. Epilepsia 56:1870–1878Google Scholar
  75. 75.
    Tupal S, Faingold C (2010) Inhibition of adenylyl cyclase in amygdala blocks the effect of audiogenic seizure kindling in genetically epilepsy-prone rats. Neuropharmacology 59:107–111Google Scholar
  76. 76.
    Ehling P, Kanyshkova T, Baumann A, Landgraf P, Meuth SG, Pape H-C, Budde T (2012) Adenylyl cyclases: expression in the developing rat thalamus and their role in absence epilepsy. J Mol Neurosci 48:45–52Google Scholar
  77. 77.
    Keravis T, Lugnier C (2012) Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. Br J Pharmacol 165:1288–1305Google Scholar
  78. 78.
    Halls ML (2018) Localised GPCR signalling as revealed by FRET biosensors. Curr Opin Cell Biol 57:48–56Google Scholar
  79. 79.
    Ellisdon AM, Halls ML (2016) Compartmentalization of GPCR signalling controls unique cellular responses. Biochem Soc Trans 44:562–567Google Scholar
  80. 80.
    Gold MG, Gonen T, Scott JD (2013) Local cAMP signaling in disease at a glance. J Cell Sci 126:4537–4543Google Scholar
  81. 81.
    Jancic D, Lopez de Armentia M, Valor LM, Olivares R, Barco A (2009) Inhibition of cAMP response element-binding protein reduces neuronal excitability and plasticity, and triggers neurodegeneration. Cereb Cortex (New York, NY: 1991) 19:2535–2547Google Scholar
  82. 82.
    Wild AR, Dell'Acqua ML (2018) Potential for therapeutic targeting of AKAP signaling complexes in nervous system disorders. Pharmacol Ther 185:99–121Google Scholar
  83. 83.
    Dema A, Perets E, Schulz MS, Deak VA, Klussmann E (2015) Pharmacological targeting of AKAP-directed compartmentalized cAMP signalling. Cell Signal 27:2474–2487Google Scholar
  84. 84.
    Calejo AI, Tasken K (2015) Targeting protein-protein interactions in complexes organized by A kinase anchoring proteins. Front Pharmacol 6:192Google Scholar
  85. 85.
    Hayes MP, Soto-Velasquez M, Fowler CA, Watts VJ, Roman DL (2018) Identification of FDA-Approved Small Molecules Capable of Disrupting the Calmodulin-Adenylyl Cyclase 8 Interaction through Direct Binding to Calmodulin. ACS Chem Neurosci 9:346–357Google Scholar
  86. 86.
    Yap KL, Kim J, Truong K, Sherman M, Yuan T, Ikura M (2000) Calmodulin target database. J Struct Funct Genom 1:8–14Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Drug Design and Pharmacology, Faculty of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark
  2. 2.Department of Technology, Faculty of Health and TechnologyUniversity College CopenhagenCopenhagenDenmark
  3. 3.Epilepsy Clinic & Neurobiology Research Unit, Copenhagen University HospitalUniversity of CopenhagenCopenhagenDenmark

Personalised recommendations